The Launch of the DARE Study in ER+/HER2– High-Risk Breast Cancer

Dr Pusztai on the Launch of the DARE Study in ER+/HER2– High-Risk Breast Cancer

Lajos Pusztai, MD, DPhil, professor of medicine, Medical Oncology, co-leader, Genetics, Genomics and Epigenetics, Yale Cancer Center, discusses the phase 2 DARE trial (NCT04567420) evaluating circulating tumor DNA (ctDNA)-guided second-line adjuvant therapy for patients with high-risk, stage II-III, estrogen receptor (ER)-positive, HER2-negative breast cancer, highlighting the importance of researching ctDNA utility in this patient population.

, investigators presented data on the use of ctDNA detection as an indicator of disease relapse. Pusztai begins by noting that the DARE study utilizing ctDNA monitoring is likely the most extensive trial of its kind. During the screening phase of the DARE trial, 542 patients were enrolled, with over 1120 ctDNA assays conducted. The median surveillance period was approximately 2 years. Out of these assays, 37 showed ctDNA-positive results, indicating a 3.3% assay positivity rate and an 8.9% positivity rate at the patient level, Pusztai explains, adding that these outcomes aligned with expectations given the rarity of recurrences and the high sensitivity and specificity of the assays. 

The ctDNA assays work by identifying relapses before clinical manifestation, Pusztai expands. Of the 37 patients with ctDNA positivity, 47% had more than 4 positive nodes, and 47% exhibited grade 3 disease or higher. Additionally, 31% of patients had T3 disease or larger and 10 patients had metastatic disease (27%), while the rest did not. Notably, earlier ctDNA studies used archived blood without concurrent imaging to show ctDNA positivity, but this trial revealed that a majority of patients in who tested ctDNA positive were imaging negative, indicating a state of minimal residual disease or molecular relapse, Pusztai emphasizes.

This research is important because of its potential implications on clinical practice, he continues. Pusztai explains that if results from the trial show that implementing this tool early and using it to guide therapy only introduces additional inconvenience and cost without enhancing recurrence-free survival, the tool may be valuable but lack meaningful clinical relevance. Conversely, a positive study outcome, ideally confirmed by independent trials, could be beneficial to the treatment paradigm, he adds. Successfully avoiding subsequent recurrence by introducing a second-line adjuvant treatment, potentially with modern endocrine regimens, would reshape treatment approaches, Pusztai states.

The DARE trial serves as an exploratory step, signaling the need for a large, definitive randomized trial with registrational intent in the future. These initial studies represent a foundational phase in uncovering the clinical utility of ctDNA monitoring, Pusztai concludes.

Videos

Lajos Pusztai, MD, DPhil, discusses the phase 2 DARE trial evaluating circulating tumor DNA-guided second-line adjuvant therapy for patients with high-risk, stage II-III, estrogen receptor-positive, HER2-negative breast cancer, highlighting the importance of researching ctDNA utility in this patient population.


Lajos Pusztai, MD, DPhil, professor of medicine and co-leader of Genetics, Genomics, and Epigenetics at Yale Cancer Center, discusses the rationale for the phase 2 I-SPY 2 trial examining the addition of durvalumab (Imfinzi) and olaparib (Lynparza) to neoadjuvant paclitaxel in HER2-negative breast cancer.

The preclinical rationale to combine PARP inhibitors with immunotherapy is quite compelling, says Pusztai. A number of mechanisms are induced by PARP inhibitors in various cell-like models and preclinical animal models that would make the pairing of these inhibitors with immunotherapy manageable. Impaired nucleotide and base excision repair increase mutation and neoantigen load, DNA fragments activate intracellular STING pathway, and PARP inhibition upregulates PD-L1 expression in breast cell lines, according to Pusztai. Three major lines of evidence led to the combination of durvalumab plus olaparib, adds Pusztai.

In the multicenter I-SPY trial, investigators sought to estimate whether the combination of durvalumab, olaparib, and paclitaxel neoadjuvant therapy would increase the pathologic complete response (pCR) rate versus chemotherapy alone in patients with high-risk HER2-negative stage II/III breast cancer.

Results presented at the 2020 AACR Annual Virtual Meeting I showed that in all patients with HER2-negative breast cancer, the predicted probability of pCR with the combination was 37% versus 20% with paclitaxel alone. When broken down by subset, the respective pCR rates were 28% versus 14% in patients with hormone receptor—positive disease and 47% versus 27% in those with triple-negative breast cancer.

Lajos Pusztai, MD, DPhil, discusses the rationale for the phase 2 I-SPY 2 trial examining the addition of durvalumab and olaparib to neoadjuvant paclitaxel in HER2-negative breast cancer.

Dr. Pusztai on Rationale for the I-SPY 2 Trial With Durvalumab/Olaparib Combo in HER2- Breast Cancer

Molecular diagnostic tests are increasingly used in the clinic to tailor therapy to the molecular characteristics of a cancer. In early stage estrogen receptor (ER)-positive cancer, the 21-gene recurrence score assay, as well as other gene expression signature-based tests are routinely used to assist in identifying patients for adjuvant chemotherapy. A new generation of tests has also been developed for ER-positive cancers to estimate the risk of late recurrence and benefit from extended adjuvant endocrine therapy and therefore identify patients who require 10 years of endocrine therapy. Among triple-negative breast cancers (TNBC), there is increasing evidence that patients with germline 

 mutant cancers are highly sensitive to platinum drugs, and inclusion of this agent with an anthracycline- and taxane-based regimen might improve their outcome. Other proposed “

-ness” markers are also being tested in the clinic. Extensive immune cell infiltra-tion (lymphocyte predominant breast cancer) that can be detected by counting tumor-infiltrating lymphocytes or measuring immune-specific gene expressions is an increasingly recognized favorable prognostic marker that also predicts greater chemotherapy sensitivity in TNBC and high-risk, ER-positive cancers. The clinical utility of immune markers is yet to be defined, but their importance will likely grow as immunotherapies are entering the clinic. In HER2-positive cancer, several markers demonstrated statistically significant associations with response to HER2-targeted therapies, but their predictive values to select one therapy over another or to omit HER2-targeted therapies are modest and have little clinical utility. Molec-ular target profiling of metastatic cancers is increasingly performed to determine clinical trial eligibility for targeted drugs and to identify potentially druggable alterations. Anecdotal examples demonstrate benefit from off-label use of targeted therapies in some patients with a matching molecular abnormality, but the clinical utility of this strategy is still under study in several ongoing clinical trials.

Clinically useful molecular diagnostic tests enable more selective use of therapies and therefore could lead to more cost-effective care and spare patients from potential side effects of ineffective therapies. In breast cancer, several diagnostic tests have emerged that meet criteria for clinical use, and many other tests are currently being investigated in clinical studies to assess their clinical value.

For estrogen receptor (ER)-positive early-stage breast cancer, molecular tests are available to assist in answering two important questions: who benefits from adjuvant chemotherapy, and who remains at risk for late recurrence despite 5-years of adjuvant endocrine therapy and therefore may require extended adjuvant endocrine therapy? The OncotypeDX 21-gene recurrence score, the Prosigna PAM50-risk-of-recurrence score, the MammaPrint gene signature, and the Breast Cancer Index each represent standardized, commercially available mRNA expression-based molecular diagnostic tests in the US that can be used to identify patients who are the most likely to benefit from adjuvant chemotherapy through measuring the expression of estrogen signaling and proliferation-related genes. The predictive utility of these tests is derived from their ability to simultaneously identify cancers that are high-risk for recurrence and also have sensitivity to chemotherapy.

The predictive value of each of these tests is supported by substantial evidence, and all major breast cancer practice guidelines support the use of multigene diagnostic assays, in conjunction with other clinical pathological parameters, to help select patients for adjuvant chemotherapy. However, when more than one assay is applied to the same cancer, they can yield discordant prediction results as often as 20 to 30% of the time, particularly for borderline risk categories.

The sample-level concordance between test results is modest because they rely on different genes, algorithms, and platforms and currently it remains unknown how to handle discordant results.

Several studies have demonstrated the cost effectiveness of these assays but the impact of test results on adjuvant chemotherapy use depends on the patient population that is being tested.

 In clinically high-risk patient populations (e.g. node-positive or >1 cm) chemotherapy use tends to decrease, while in the low-risk populations (e.g. node-negative and <1 cm) chemotherapy use increases among patients who had testing compared to those who were not tested.

Overall, at least half of all metastatic recurrences of ER-positive breast cancers occur after 5 years. Several randomized clinical trials reported improved recurrence-free survival (RFS) with extended endocrine treatment using tamoxifen or an aromatase inhibitor (ATLAS, MA.17, aTTom, NASBP-B33, ABCSG6a) and one study (ATLAS) also showed improved overall survival with 10 years of tamoxifen compared to 5 years.

 However, the absolute benefit is small (2 to 3% improvement in RFS) and extended endocrine therapy implies financial costs and increased risk for adverse events.

 For example, in the ATLAS trial, 340 patients needed to be treated to prevent six deaths from breast cancer while the treatment caused approximately three extra endometrial cancers and one extra pulmonary embolism. Several emerging molecular tests can identify patients who are at risk for late recurrence including the Breast Cancer Index (BCI), the Prosigna PAM50 Risk of Recurrence (ROR) score, and the EndoPredict test (available in Europe).

Typically, patients with high proliferation scores and high estrogen-related gene expression or low proliferation scores and low estrogen-related gene expression are at the greatest risk for late recurrences.

Unlike the other tests in this space, the BCI has also been shown to predict benefit from extended endocrine therapy in archived samples of the MA17 trial that compared 5 years of tamoxifen with 5 years of tamoxifen followed by 5 years of letrozole and therefore may be particularly helpful to identify patients for extended endocrine therapy.

 A study that examined the impact of BCI results on medical decision making showed that physician recommendations for extended endocrine therapy changed for 25% of patients after considering BCI results, with a net decrease in extended endocrine therapy.

 Testing also led to increased patient satisfaction, decreased decision conflict and anxiety, and resulted in fewer patients wanting to receive extended therapy.

Efforts are also under way to develop tertiary risk predictors that could measure residual risk of recurrence after completion of adequate adjuvant endocrine and chemotherapies. Current molecular diagnostic tests such OncotypeDx, Prosigna PAM50-ROR score, BCI, etc. identify patients who are high risk for recurrence with endocrine therapy alone and therefore good candidates for adjuvant chemotherapy. However, many but not all of these patients will revert to low-risk status after completing chemotherapy. Identifying those who remain at high risk for recurrence despite the best current therapies is important because it defines the ideal patient population for adjuvant clinical trials. One study demonstrated the feasibility of this approach by re-stratifying OncotypeDx high-risk patients who all received endocrine plus chemotherapy, into good versus poor prognosis groups with 5-year RFS of 95% and 76%, respectively, using a multigene signature.

No clinically meaningful molecular prognostic tests emerged for triple-negative breast cancer (TNBC) despite extensive research. The prognostic assays that are used in ER-positive cancers invariably categorize ER-negative tumors as high risk. Immune cell infiltration is currently emerging as a prognostic and chemotherapy predictive marker in TNBC. High tumor-infiltrating lymphocyte (TIL) count or high expression of immune gene signatures are consistently associated with better survival.

 Additionally, neoadjuvant studies demonstrated significantly higher pathological complete response (pCR) rates among immune-rich compared to immune-poor TNBC indicating a chemotherapy response predictive role.

 An international guideline was recently published to standardize TIL assessment, preparing the stage for introducing this prognostic variable into routine pathology reporting.

A substantial amount of preclinical data suggest the many TNBC harbor DNA repair deficiencies, and therefore drugs that induce DNA damage may be particularly effective. Clinical trials in the neoadjuvant and metastatic treatment settings demonstrated that platinum drugs have activity in TNBC, but overall these drugs are not more effective than other active agents such as taxanes.

In an attempt to identify the subset of patients with TNBC that may be particularly sensitive to DNA-damaging agents, several molecular tests are being developed that quantify DNA repair deficiency. One of the most extensively studied assays is the Homologous Recombination Deficiency (HRD) score, which combines three different consequences of DNA repair defect on DNA structure including loss of heterozygosity, telomeric allelic imbalance, and large-scale state transition metrics, into a single HRD score.

 This score is highly correlated with the presence of germline 

 promotor methylation but the score can also be high in 

Studies have shown that a high score is predictive of response to platinum therapy in TNBC and ovarian cancer, but it also seems to be associated with more general chemotherapy sensitivity including anthracycline and taxane-based regimens.

 Studies have shown that a high score is predictive of response to platinum therapy in TNBC and ovarian cancer, but it also seems to be associated with more general chemotherapy sensitivity including anthracycline and taxane based regimens 

. A randomized phase III trial that compared single-agent carboplatin with docetaxel as first-line therapy for metastatic TNBC revealed that both drugs were equally effective and a high HRD score could not define the subpopulation that was more sensitive to platinum than to the docetaxel. However, in the 

 positive population, carboplatin showed a significantly increased activity compared to docetaxel.

 These results are consistent with the reported high activity of Cisplatin in 

positive stage I to III breast cancer in neoadjuvant trials.

 Several correlative studies are under way to further define the predictive value of the HRD score as well as other similar DNA damage signatures, and based on the currently available data, germline BRCA status appears to be the best predictor of “above average” sensitivity to platinum drugs in breast cancer.

Despite extensive clinical efforts and some impressive preclinical models, there are no currently clinically useful molecular predictors to select one HER2 targeted therapy over another or to recommend against using HER2 targeted therapy in HER2-positive breast cancers. Several neoadjuvant and metastatic trials have demonstrated that mutations in the phosphatidylinositol 3-kinase catalytic subunit (PIK3CA) and extensive immune cell infiltration are negative and positive predictors of pathologic complete response to HER2 targeted therapies, respectively.

 However, their positive and negative predictive values are modest and they also appear to interact with prognosis independent of treatment response, which limits their clinical utility. Other molecular predictors of response have also been proposed based on biological insights into the mechanisms of resistance to HER2 targeted therapies including altered expression and structure of the HER2 receptor, constitutive activation of the downstream signaling pathways, and switching to alternative growth and survival pathways, but none of these have been validated consistently in clinical studies.

	Molecular Target Profiling of Metastatic Breast Cancer

Molecular target profiling of metastatic cancers is increasingly performed in the clinic to identify potentially druggable alterations. Many clinical trials require testing for particular molecular defects that may sensitize cancers to an investigational drug as part of their eligibility criteria, and anecdotal case histories demonstrate benefit from off-label use of targeted therapies in some patients with a matching molecular abnormality. There are several CLIA-certified academic and commercial molecular pathology laboratories (eg, Foundation Medicine, Caris Life Sciences, Paradigm PCDx) that provide targeted next- generation sequencing (NGS) or a combination of NGS and other methods to perform drug target profiling. The analytical validity of the commercial assays is often published but the clinical validity (ie, response predictive value) and clinical utility (ie, demonstration of improved patient outcome because of using a test) in solid tumors have not been established beyond a few mutations in melanoma (

A central premise behind cancer target profiling is that tumors that share the same driver mutation will respond to a corresponding targeted drug regardless of histologic subtype whereas cancers without the mutation will not. Laboratory experiments and a few clinical success stories support this hypothesis (eg, trastuzumab activity in HER2 amplified gastric cancer), but there are also numerous clinical studies indicating that the target function of a given gene or mutation is molecular context- and cancer type-dependent (eg, low tamoxifen activity in ER-positive ovarian cancer, lack of vemurafenib activity in BRAF mutant in colon cancer).

Furthermore, each cancer harbors a large number of potential functionally important genomic alterations, which makes it difficult to designate a single abnormality as the driver event.

 Comparative genomic hybridization studies showed that the genome of an average breast cancer contains 76 large-scale copy number alterations; exome sequencing studies showed at least 30 to 80 deleterious single nucleotide mutations

 and these somatic events arise in the background of several thousand high functional impact germline single-nucleotide polymorphisms that each individual carries.

 This complexity of the cancer genome, along with the numerous redundant and compensatory biological pathways, may explain the modest correlation between the activity of many targeted drugs and alterations in their corresponding targets. For example, there is only modest correlation between PI3K mutation status and benefit from mTOR or PI3K inhibitors.

There is also little correlation between CDK 4/6 amplification and benefit from CDK 4/6 inhibitors.

 Despite the mixed success, systematic testing of this concept in prospective clinical trials is important. Several nationwide industry-sponsored clinical trials including the Signature trial by Novartis (www.signaturetrial. com), the My Pathway trial by Genentech (http://clinicaltrials. gov/show/NCT02091141), the NCI-MATCH (www.ctsu.org), and the ASCO TAPUR (TAPUR@asco.org) trial, are currently open for patients with breast cancer to determine the clinical value of a broad spectrum of molecularly targeted therapies and the clinical utility of cancer target profiling.

In summary, the past decade of biomarker research has led to the introduction of several multigene prognostic tests that are now routinely used in clinical decision making to assist the se-lection of patients for adjuvant chemotherapy, and several other tests have emerged with potential clinical utility. In recognition of these advances and to help physicians use molecular diagnos-tics wisely, ASCO has recently issued new recommendations for biomarker use in early-stage breast cancer.

The guideline summarizes the type and quality of evidence that supports the recommendations, which are further qualified by levels of strength. The ASCO guideline states that the clinician either “may use” or “should not use” a particular assay. The ASCO recommendations are listed in the TABLE, along with the positions of other practice guidelines (NCCN and St Galen) on the same tests. While the ASCO guidelines provide practical clarity, they do not do full justice for the available evidence for some uses of these tests. For example, the recommendation that genomic prognostic tests developed for ER-positive cancer (OncotypeDx, etc.) should not be used in TNBC is based on consistent and broad evidence that demonstrated no clinically meaningful risk stratification function in this disease setting. On the other hand, the recommendation that these tests should not be used in patients with one or two positive nodes is based on well-reasoned caution even though multiple studies consistently demonstrated continued independent, prognostic function in node-positive patients and some of the tests even provide nodal status-adjusted risk estimates. Similarly, the guideline recommends against using any of the tests endorsed for risk prediction in ER-positive cancer to guide selection of extended adjuvant therapy, despite multiple publications supporting their ability to predict late recurrences, and in the case of at last one assay, there is a data to suggest that those at high risk for late recurrence also benefitted from extended endocrine therapy. Practicing oncologists often encounter clinical scenarios when test results with some degree of uncertainty still provide helpful information when considered together with other (often similarly uncertain) disease-related variables. Several emerging tests with proven analytical and clinical validly but yet uncertain clinical utility occupy that space.

: Marie-Kristin von Wahlde, MD, is from Section of Breast Medical Oncology at Yale Cancer Center, New Haven, CT, and Department of Obstetrics and Gynecology at University Hospital Münster, Germany. Tomoko Kurita, MD, Tara Sanft, MD, Erin Hofstatter, MD, and Lajos Pusztai, MD, DPhil, are from Section of Breast Medical Oncology at Yale Cancer Center, New Haven, CT.

: Dr. Sanft received research funding from BioTheranostics. LP Dr. Pusztai received research support from Foundation Medicine. Dr. von Wahlde is supported by a research fellowship from the German Research Foundation.

: Lajos Pusztai, MD, DPhil, Yale Cancer Center, Section of Breast Medical Oncology, 300 George St., New Haven, CT, 06511; email: lajos.pusztai@yale.edu

			Iwamoto T, Lee J-S, Bianchini G, et al. First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. 

 2011;130(1):155-164. doi: 10.1007/s10549-011-1706-9.

			Kelly CM, Bernard PS, Krishnamurthy S, Wang B, et al. Agreement in risk prediction between the 21-gene recurrence score assay (OncotypeDX(R) and the PAM50 breast cancer intrinsic classifier in early stage ER-positive breast cancer. 

			Bartlett JM, Stein RC, Bayani J, et al. Abstract P4-11-07: Comparison of multiparameter tests in the UK OPTIMA-Prelim trial.

. 2015;75(9 Supplement):P4—11–07–P4–11–07.

			Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. 

			Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI. Costeffectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. 

. 2010;15(5):457-465. doi: 10.1634/theoncologist.2009-0275.

			Hassett MJ, Silver SM, Hughes ME, et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. 

 2012;30(18):2218-2226. doi: 10.1200/JCO.2011.38.5740.

			Pusztai L: Breast cancer: Chemotherapy and the recurrence score-results as expected? 

. 2015;12(12): 690- 692. doi: 10.1038/nrclinonc.2015.191.

			Blok EJ, Derks MG, van der Hoeven JJ, van de Velde CJ, Kroep JR. Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence. 

. 2015;41(3):271-276. doi: 10.1016/j.ctrv.2015.02.004.

			Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. 

			Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. 

. 2013;14(11):1067-1076. doi: 10.1016/S1470-2045(13)70387-5.

			Sgroi DC, Carney E, Zarrella E, et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.

. 2013;105(14):1036-1042. doi: 10.1093/jnci/djt146.

			Sanft T, Aktas B, Schroeder B, et al. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer. 

. 2015; 154(3), 533-541. doi: 10.1007/s10549-015-3631-9.

			Bianchini G, Pusztai L, Karn T, et al. Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. 

			Sestak I, Cuzick J, Dowsett M, et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. 

 2015;33(8):916-922. doi: 10.1200/ JCO.2014.55.6894.

			Khan SS, Karn T, Symmans WF, et al. Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers. 

. 2015;149(3):789-797. doi: 10.1007/s10549-015-3277-7.

			Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. 

2013;31(7):860-867. doi: 10.1200/JCO.2011.41.0902.

			Bianchini G, Qi Y, Hugo AR, et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. 

. 2010;28(28):4316-4323. doi: 10.1200/JCO.2009.27.2419.

			Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

			Dieci MV, Criscitiello C, Goubar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. 

. 2014;25(3):611-618. doi: 10.1093/ annonc/mdv241.

			West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. 

. 2011;13(6):R126. doi: 10.1186/ bcr3072.

			Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

 2010;28(1):105-113. doi: 10.1200/JCO.2009.23.7370.

			Denkert C, Minckwitz von G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. 

. 2015;33(9):983-991. doi: 10.1200/ JCO.2014.58.1967.

			Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. 

. 2015;26(2):259-271. doi: 10.1093/annonc/ mdu450.

			Tutt A, Ellis P, Kilburn L, et al. Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). 

 2015;75(9 Supplement):S3—01– S3–01.

			Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. 

. 2010;28(7):1145-1153. doi: 10.1200/JCO.2009.22.4725.

			Minckwitz von G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

 2014;15(7):747-756. doi: 10.1016/S1470-2045(14)70160-3.

			Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

 2015;33(1):13-21. doi: 10.1200/JCO.2014.57.0572.

			Rugo HS, Olopade O, DeMichele A, et al. Abstract S5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL. Cancer Res. 2013;73(24 Supplement):S5—02–S5–02.

			Timms KM, Abkevich V, Hughes E, et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. 

. 2014;16(6):475. doi: 10.1186/s13058-014-0475-x.

			Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. 

2012;107(10):1776-1782. doi: 10.1038/bjc.2012.451.

			Birkbak NJ, Wang ZC, Kim J-Y, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. 

 2012;2(4):366-375. doi: 10.1158/2159-8290.CD-11-0206.

			Popova T, Manié E, Rieunier G, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. 

. 2012;72(21):5454-5462. doi: 10.1158/0008-5472.CAN-12-1470.

			Byrski T, Huzarski T, Dent R, et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. 

 2014;147(2):401-405. doi: 10.1007/s10549-014-3100-x.

			Perez EA, Ballman KV, Tenner KS, et al. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. 

 October 2015:1-9. doi: 10.1001/jamaoncol.2015.3239.

			Majewski IJ, Nuciforo P, Mittempergher L, et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

 2015;33(12):1334-1339. doi: 10.1200/ JCO.2014.55.2158.

			Loibl S, Minckwitz von G, Schneeweiss A, et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

2014;32(29):3212-3220. doi: 10.1200/JCO.2014.55.7876.

			Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. 

			Kopetz S, Desai J, Chan E, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. ASCO Meeting Abstracts. 2010;28(15_suppl):3534.

			Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. 

			Andre F, Job B, Dessen P, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. 

 2009;15(2):441-451. doi: 10.1158/1078-0432.CCR-08-1791.

			Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. 

. 2012;490(7418):61-70. doi: 10.1038/nature11412.

			Agarwal D, Qi Y, Jiang T, et al. Characterization of DNA variants in the human kinome in breast cancer. 

			Treilleux I, Arnedos M, Cropet C, et al. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. 

2015;26(1):120-125. doi: 10.1093/annonc/mdu497.

			Hortobagyi GN, Chen D, Piccart M, et al. Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from BOLERO-2.

 October 2015:JCO.2014.60.1971. doi: 10.1200/ JCO.2014.60.1971.

			Mayer IA, Abramson VG, Isakoff SJ, et al. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

 2014;32(12):1202-1209. doi: 10.1200/ JCO.2013.54.0518.

			Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

2012;30(8):777-782. doi: 10.1200/JCO.2011.36.1196.

			Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. 

			Finn RS, Crown JP, Láng I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. 

. 2015;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3.

			Harris LN, Ismaila N, McShane LM et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. 

Articles

The past decade of biomarker research has led to the introduction of several multigene prognostic tests that are now routinely used in clinical decision making to assist the se-lection of patients for adjuvant chemotherapy, and several other tests have emerged with potential clinical utility.  

Clinical Utility of Emerging Molecular Diagnostics in Breast Cancer

Lajos Pusztai, MD, DPhil, professor of Medicine (Medical Oncology), chief, Breast Medical Oncology, co-director, Cancer Genetics Research Program, Yale Cancer Center, discusses the Breast Cancer Index (BCI) in patients with ER-positive/HR-positive breast cancer.

Tumor size and nodal status are not accurate predictors of which patients are at high risk for disease recurrence after five years from initial therapy, Pusztai explains. Prediction tools such as Adjuvant Online and the Recurrence Score assay make predictions over a 10-year period, but do not separate risks for early- or late recurrence.

The BCI is a molecular assay that was designed to help with this decision-making dilemma, Pusztai adds. This tool has led researchers to believe that ER-positive patients with a high proliferation index will benefit from extended endocrine therapy. Three randomized trials demonstrated that the assay does help identify patients at high risk for late recurrence. The MA.17 trial, for example, also showed that extended endocrine therapy in these patients demonstrates an improvement in recurrence-free survival.

Lajos Pusztai, MD, DPhil, professor of Medicine (Medical Oncology), chief, Breast Medical Oncology, co-director, Cancer Genetics Research Program, Yale Cancer Center, discusses the Breast Cancer Index in patients with ER-positive/HR-positive breast cancer.


Lajos Pusztai, MD, DPhil

Articles

Dr Pusztai on the Launch of the DARE Study in ER+/HER2– High-Risk Breast Cancer

Dr. Pusztai on Rationale for the I-SPY 2 Trial With Durvalumab/Olaparib Combo in HER2- Breast Cancer

Clinical Utility of Emerging Molecular Diagnostics in Breast Cancer

Dr. Pusztai Discusses BCI in Patients With ER-Positive/HR-Positive Breast Cancer